Anatara Lifesciences Ltd (ASX:ANR) provides the Chairman's address to shareholders.
Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.
Anatara Lifesciences Ltd (ASX:ANR) Dr Tracey Mynott Presents at TRI Science Business Inspiration Series
Anatara Lifesciences (ASX:ANR) CSO, Dr Tracey Mynott, was recently invited to present at the Translational Research Institute's Science Business Inspiration Series. The series was launched with Session 1 "The whole journey: from idea to reality".
Anatara Lifesciences (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Anatara Lifesciences Ltd (ASX:ANR) provides the Company's Annual Report 2017 Update.
Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.
Anatara Lifesciences Ltd (ASX:ANR) and Zoetis to Negotiate Terms of International Detach(R) Commercial Agreement
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that global animal health company, Zoetis Inc. has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R), with terms to be agreed.
FINANCE VIDEO: Anatara Lifesciences Ltd (ASX:ANR) Gold Coast Investment Showcase Investor Presentation
Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).
Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide investors with an update on recent progress.
An oral drench to protect piglets from gut infection could soon be available to pig farmers. It's been developed by scientists and is made from pineapples - taking antibiotics out of the food chain.